Abeona Therapeutics Has Submitted A Biologics License Application To The FDA Seeking Approval Of EB-101 For Recessive Dystrophic Epidermolysis Bullosa
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics has submitted a Biologics License Application to the FDA for approval of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa.
September 26, 2023 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics has submitted a Biologics License Application to the FDA for EB-101. This could potentially open a new revenue stream if approved.
The submission of a Biologics License Application to the FDA is a significant step towards commercialization of a product. If approved, EB-101 could provide a new revenue stream for Abeona Therapeutics, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100